RxSpan MD Reviews: $249 Is the Month, $150 Is a Year

The one-sentence version

RxSpan MD publishes an all-inclusive price for NAD+ — consult, medication, supplies, shipping and support in one figure — and the month-to-month rate is $249, with $199, $166 and $150 available only on three-, six- and twelve-month plans. It is a physician-founded practice that names its founder — rare here — and it names all four of the pharmacies that may fill your prescription, with phone numbers — while never saying what kind of facility any of them is. It grades A, 13 out of 14; the missing point is the compounding standard it never states.

What it is, and who it's for

RxSpan MD is a telehealth practice founded by Dr John Diaz, a board-certified plastic surgeon with more than twenty years in practice — Cornell, Albert Einstein College of Medicine, Alpha Omega Alpha, five years as president of the Society of Plastic Surgeons. His page frames the origin honestly: patients came for appearance and asked about weight and wellness, and the practice grew into "helping patients extend their healthspan through thoughtfully prescribed medications." Naming a clinician at all puts RxSpan ahead of most of this field — see what a longevity doctor actually is.

Its longevity catalog is wide: NAD+ by injection, nasal spray and flex-dose tablet, sermorelin ODT, glutathione, GHK-Cu, methylene blue, MIC B12, Lipo C and PT-141, beside a weight-loss line running from compounded semaglutide up to brand Wegovy at $1,349.

What it actually costs

The catalog. NAD+ Injection $249, NAD+ Nasal Spray $249, NAD+ Flex Dose Tablet $199, Sermorelin ODT $179, Glutathione $149, GHK-Cu $149, Lipo C $179, PT-141 $199, MIC B12 $129, Methylene Blue $99. Every single one of those numbers carries the same parenthetical beneath it: "(For the first month)."

The plan ladder behind it. Choosing a product opens a plan selector: Monthly $249/mo · 3-month plan $199/mo · 6-month plan $166/mo · 12-month plan $150/mo, with the three longer terms flagged "Max Saving." The overview beside it reads "Pre-paid monthly or quarterly," "Price includes consult, medication, supplies, shipping, and support," and "Cancel or change plans anytime."

So the honest summary is two sentences. $249 is a real, published, all-inclusive month-to-month price for NAD+ injection — better disclosed than most providers here, and the top of its range. Everything cheaper is a prepay, and the "(For the first month)" label means the catalog number is not by itself a monthly commitment either.

You pay before you are assessed. The checkout footer states: "After checkout, a provider will review your information to determine if treatment is right for you. Prescription is not guaranteed." The default plan selection totals $597 — three months at $199. That is the number a buyer who clicks through without changing anything is charged, not $249 and certainly not $150.

And there is no refund policy. RxSpan publishes four legal documents — Terms of Service, Privacy Policy, Notice of Privacy Practices and Medical Consent — and none is a refund or cancellation policy. What happens to your $597 if the provider declines you is not stated anywhere public. Ask before you check out; see also what longevity care costs.

What's included, what's extra

Included, per the site: the consult, the medication, supplies, expedited shipping, and "unlimited appointments, messaging and support" with "24/7 access to a dedicated team of specialists." Sitewide badges promise "No Hidden Fees" and "Doctor-led Plans & Coaching."

Not offered: bloodwork, biomarker panels or any before-and-after testing. Nothing here measures whether the protocol did anything — the same structural gap most of this category has, and the reason longevity biomarker panels sit outside it.

Clinical oversight and the pharmacy

Oversight is genuinely above average on the disclosure axis: a named, credentialled founding physician, unlimited clinician access inside the price, and an explicit statement that a prescription is not guaranteed.

RxSpan does name its pharmacies. The answer is in RxSpan's FAQ, which fills in a moment after the page opens — easy to miss, but published.

Asked "Who are your Pharmacy Providers?", RxSpan names four, each with a dialable number: Belmar Pharmacy (800-525-9473), Strive Pharmacy (855-405-5993), Epiq Scripts (833-654-3553) and Casa Pharma Rx (877-937-6868). The same source names the clinical team — Lion MD, with Dr Ana Lisa Carr, MD and Dr Kelly Tenbrink, MD, both with published NPI numbers. On disclosure, that puts RxSpan ahead of most providers here rather than behind it.

Two caveats belong beside it, and they are the reason this is the middle rung and not the top. It classifies none of them. No Section 503A claim, no 503B claim, no compounding standard of any kind appears anywhere on the site — so you know who may fill the prescription and not to what standard. And the disclosure is real but not exclusive: the identical four are published by Care Bare Rx, Synergy Rx, Breeze Meds and Sunlight, all running on the same CareValidate backend. It is one shared bench, not four independent attestations. Naming without classifying is the middle rung of our rubric — one point of two, and the only point RxSpan drops.

One thing travels with the name. Belmar, one of the four, received an FDA warning letter addressed to Belmar Pharma Solutions, Drug Depot, LLC., dba APS Pharmacy in March 2023, and the FDA closed it out in October 2023 — so there is no open letter against the pharmacy. RxSpan MD itself holds no FDA warning letter, and neither does Care360, its platform vendor. You can only check a fact like the Belmar letter because RxSpan names its pharmacies — which is the point of naming them.

Why that is not a formality: 503A compounders are state-licensed and specifically not subject to current good manufacturing practice requirements, while 503B outsourcing facilities register with FDA and must comply with them. Compounded drugs of either class are not FDA-approved¹ — and a buyer cannot look up a facility RxSpan will not name.

What the research says, in short

RxSpan's own copy is restrained — it sells "healthspan" rather than reversal — and that is the right register, because human evidence that NAD+ or sermorelin slows aging is thin. Injected NAD+ has very little outcome data, so there is no good research case for paying more for the injection than for the tablet. Sermorelin raises your own growth hormone; whether that improves anything you would notice in healthy adults is unproven. The detail is in NAD+ for longevity, peptides for longevity and what's proven versus hyped.

Where it's weak, and who should skip it

Skip it if you need to know what kind of facility compounds your medication — RxSpan names the four candidates but classifies none of them, and never says which one fills your particular order. Skip it if paying before assessment with no published refund policy is a risk you will not take. And skip it if $249 is simply too much: it sits near the best options here's month-to-month range for NAD+, and two A-graded competitors sit well below it.

If you proceed, choose the Monthly plan deliberately rather than accepting the $597 default, and ask two questions in writing first: which of the four named pharmacies fills your prescription and under what compounding standard, and what happens to your money if the provider declines you.

The verdict, against the rubric

Our rubric scores five things out of fourteen: price transparency (4), a genuine longevity line (4), clinical oversight (2), pharmacy disclosure (2) and human support (2). RxSpan MD takes price transparency in full — one all-inclusive figure per product with the plan ladder shown, which is more than most providers here manage — plus four for a real longevity line, two for a consult inside the price, and two for unlimited clinician access. It takes one of two on pharmacy — it names four dispensing facilities with phone numbers, which is the middle rung, but states no compounding standard for any of them, which is the top one. Thirteen of fourteen. An A.

The letter is right and the shape of it is unusual: this is among the most disclosure-forward rows we grade — founder, clinicians, NPIs and four pharmacies — and it still will not say what kind of pharmacy any of them is. State a compounding standard for the four it already names and it would be a fourteen tomorrow, without changing a single price. The full graded field is at our provider rankings; its neighbors are our Direct Meds review and Enhance MD review.